Issue 7 2021

Issue 7 2021 29 encouraging everyone to do independent work while also keeping in mind the team mindset that underpins it. Over the course of Covid-19, Exom saw its industry begin to shift its attitude towards accepting digital clinical trials. Due to this, it has been able to ply its trade more and convert more of its market segment to how much digitally-enabled clinical trials can make the experience so much easier and more effective. However, it is still an uphill battle on occasion, and the international clinical field has a long way to go before acceptance is reached – one needs to glance at the EMA and FDA guidelines to see the proof of this – and Exom, therefore, is championing a mixed approach of on-site and digital monitoring. Forever working towards its overall mission, Exom will continually create and develop more ways to implement digitization into its field in 2021. As it moves forward into the rest of the year, it will be keeping its three essential stakeholders, their patients, their investigators, and their sponsors, at the core of its work, supporting them as much as possible with new technologically enabled workflows. It will also be working harder on Genius ROSA, allowing it to further establish itself as a telemedicine tool that uses artificial intelligence to generate control groups and so much more. Transitioning from typical data management to all new data science as a service and performing its so-called Clinical Trial 5.0 to combine human ingenuity with technology is looking forward to bettering its provision of value-added, exemplary services. Company: Exom Group Srl Contact: Luigi Visani Website: exomgroup.com